Are N-of-1 Trials an Economically Viable Option to Improve Access to Selected High Cost Medications? The Australian Experience  by Scuffham, Paul A. et al.
Are N-of-1 Trials an Economically Viable Option to
Improve Access to Selected High Cost Medications?
The Australian Experience
Paul A. Scuffham, PhD, PG, Dip, BA,1 Michael J. Yelland, MB, BS, PhD, FRACGP, FAFMM,1 Jane Nikles, MBBS,2
Eva Pietrzak, PhD,3 David Wilkinson, BSc(Hons), MBChB, MSc, MD, PhD, DSc, FRACGP, FAFPHM, MRCP4
1School of Medicine, Grifﬁth University, Meadowbrook, Qld,Australia; 2School of Medicine,The University of Queensland, Herston, Qld,
Australia; 3School of Population Health,The University of Queensland, Herston, Qld,Australia; 4School of Medicine,The University of
Queensland, Herston, Qld,Australia
ABSTRACT
Objective: To explore the economic viability of N-of-1 trials
for improving access to selected high cost medications in
Australia.
Methods: Cost and effectiveness estimates were derived from
two N-of-1 trials conducted by The University of Queensland
from 2003 to 2005—celecoxib versus sustained-release
paracetamol for osteoarthritis in a general practice setting
and gabapentin versus placebo for chronic neuropathic pain
in a hospital setting. Effectiveness was determined by the
proportion of responders to each medication. The costs of
trials were offset against the savings generated by subsequent
changes in prescribing. Decision analysis models with semi-
Markov processes were used to compare different scenarios
of N-of-1 trials versus usual care.
Results: The ﬁxed cost of performing N-of-1 trials was
approximately AUS$23,000 for each trial and the variable
cost was approximately AUS$1300 per participant. Clinical
outcomes favored celecoxib over paracetamol in 17% of
participants and gabapentin over placebo in 24% of partici-
pants. Modeling these results showed that the cost-offsets
from efﬁcient use of medications were less than the cost of
running a trial; however, the incremental costs per quality-
adjusted life-year gained were AUS$6,896 and AUS$29,550
for the gabapentin/placebo and celecoxib/paracetamol trials,
respectively, over a 5-year horizon. Key factors affecting the
viability were the time horizon modeled, the variable cost per
participant, the probability of response to the intervention
medication, and rates of use in nonresponders and the usual
care alternative.
Conclusions: The N-of-1 strategy offers a realistic and viable
option for increasing access to selected high cost medications
where the medications are used for the symptomatic treat-
ment of chronic disease, have rapid onset of action, and
clinical response is unpredictable without a trial.
Keywords: celecoxib, chronic neuropathic pain, cost-
effectiveness, gabapentin, N-of-1 trials, osteoarthritis.
Introduction
Over the last 10 years there has been increasing
concern about the high psychosocial, economic and
health costs of inappropriate medication use. In Aus-
tralia, the Pharmaceutical Beneﬁts Scheme (PBS) is the
government scheme that subsidizes common prescrip-
tion medications. The growth of Government expen-
diture on subsidized medications listed on the PBS is of
increasing concern. For the year ending 30 June 2004
PBS expenditure totaled AUS$5 billion, a 9.3%
increase compared with the previous year [1]. In the
same period, total PBS prescription volumes increased
only by 4.3%.
There is a need to control government expenditure
while still making medications available to those in
whom they will be effective. Consequently, recommen-
dations for listing of medications on the PBS by the
Pharmaceutical Beneﬁts Advisory Committee (PBAC)
are heavily based on high-level evidence from random-
ized controlled trials. Typically these trials deﬁne the
mean response in a group of participants; however, the
variation in response within these groups may be large
and it may be impossible to predict response at the
individual level. It is well known that drug trials can be
performed on younger and/or healthier sufferers of a
particular disease and there can be differences between
the trial groups and the ultimate target groups of a
given medication, for example, [2,3]. Evidence from
population-based trials may result in the long-term
prescription of expensive medication to individuals
for whom it is not effective or even harmful, leading to
suboptimal cost-effectiveness and wastage of resources.
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When applying economic data within a formal
approvals process, such as that used by the PBAC, an
overall estimate of the incremental cost per unit of
health beneﬁt gained is provided in the form of the
incremental cost-effectiveness ratio—ICER, effectively
averaging across responders and nonresponders. In
reality the cost to gain a unit of health beneﬁt among
responders will be very low whereas that among non-
responders will be very high. What options then exist
for more effective “targeting” of drug treatments, espe-
cially in the era of very high cost medications, which
may offer marginal beneﬁts to a large group (but very
high beneﬁt to small numbers of patients), and may
also have signiﬁcant side effects?
Current targeting strategies may be less than
optimal because they rely on identifying characteristics
of groups of patients who are likely to have a higher
response rate. Nonresponders are still included in this
target group and potential responders may be
excluded. For a few medications, genetic testing to
identify potential responders is becoming important;
however, this approach is currently limited. For some
medications, such individualized targeting can only be
obtained through N-of-1 trials. N-of-1 trials provide
empirical data of individual responses to treatment.
These are within-patient randomized, double-blind,
cross-over comparisons of two treatment regimens
(one of which may be placebo), in which patients act as
their own controls [4]. The N-of-1 trial offers the
highest level of evidence for the individual on the effec-
tiveness of long-term medications used for symptom-
atic treatment of stable chronic conditions [5].
The use of N-of-1 trials in routine prescribing
could potentially produce ﬁnancial savings, depend-
ing on ﬁve factors: the cost of the medication, the
duration of use of the medication, the proportion of
responders, the proportion of nonresponders who
continue medication and the cost of undertaking the
trials. Potential ﬁnancial savings to the PBS are likely
to be greater where response rates are relatively low.
If nonresponders cease their medication, morbidity
and mortality from medication-related adverse
events, and costs to the health-care system would be
greatly reduced. Early identiﬁcation of nonresponders
has the potential to reduce the cost per unit of effect
gained in responders, improving the cost-effectiveness
of the medication. It shifts resource allocation deci-
sions to the level of the individual patient—to the
margin [6].
A thoughtful article by Karnon discusses the poten-
tial of N-of-1 trials in the estimation of individualized
cost-effectiveness and uses hypothetical examples [6].
Larson et al. ran an N-of-1 trial service from 1991 to
1993 in the United States [4]. Crude estimates of
resource consumption including time-motion studies
estimated that total costs per trial would likely be $400
to $500 in 1990 US dollars. They did not calculate
savings that might result from the trials that led to
discontinuation of chronic medications or the avoid-
ance of side effects. Guyatt and colleagues who also
offered an N-of-1 trial service in the United States
found that a substantial proportion of trials resulted in
discontinuation of medication that would otherwise
have been continued for months or years [7].
Until now there has been only one report of a
formal economic evaluation of N-of-1 trials. This is a
recent randomized controlled trial from Canada,
which showed that N-of-1 trials with diclofenac/
misoprostol produced slightly better health outcomes
(as measured by the Health Assessment Questionnaire
for pain and disability, WOMAC scales, and physi-
cian global assessments), although were more time-
consuming and expensive over a relatively short
time horizon (6 months), than standard treatment in
osteoarthritis (OA) (cessation of NSAID with recom-
mencement if symptoms worsened) [8]. This small
study had some important limitations. The numbers
were small—there were 25 patients in one group and
24 in the other and there was a high dropout rate from
the N-of-1 trial group (18 out of 24 did not complete
3 crossovers). The higher costs for the N-of-1 group
(from US$60 to $160 more per patient) were due to
higher costs of medications, nurse and physician time,
and travel costs.
Our study aimed to determine the economic
viability of N-of-1 trials of medications for symptom-
atic treatment of stable chronic conditions in the
Australian context, in both hospital and community
settings.
Methods
In 2003 to 2005, the N-of-1 trial service at The Uni-
versity of Queensland conducted two N-of-1 trials.
The ﬁrst compared celecoxib with sustained release
paracetamol (SR paracetamol) for osteoarthritis and
was performed in general practices throughout Austra-
lia. The second compared gabapentin with placebo for
chronic neuropathic pain and was performed in out-
patient clinics in two Australian hospitals.
The duration of each trial was 12 weeks, compris-
ing three 4-week cycles with a fortnight on each medi-
cation assigned in a random order (e.g., 2 weeks of
celecoxib followed by 2 weeks of SR paracetamol).
The choice of three pairs of treatment periods is
regarded as the best compromise between statistical
certainty and patient acceptability. With one pair, the
chance of a false positive or false negative result is up
to 50%, but with three pairs this reduces to 12.5%.
More than three cycles makes the trials unacceptably
long and expensive. Trials could be stopped early in
cases of severe adverse reactions or if symptoms
became intolerable.
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Patients were randomized to their starting medica-
tion in blocks of four. Five variables were monitored in
each cycle—pain, stiffness (for celecoxib/paracetamol
trials) or sleep interference (for gabapentin/placebo
trials), functional limitation, frequency of adverse
events, and preferred medication. Differential re-
sponses in pain, stiffness, sleep interference and
functional limitation responses were determined by
minimum clinically detectable differences [9–11] for
adverse events by a lower frequency on one medication
in at least two cycles and for medication preference by
a preference for one medication in at least two cycles.
The overall response status of each patient was then
based on an equal weighting of the differential
response for each variable [12,13]. Participants and
their doctors were sent a comprehensive report of the
results within 2 weeks of completion of the last cycle.
This was used to inform, but not dictate, future medi-
cation usage. Ethics approval for both trials was
obtained from The University of Queensland’s
Medical Research Ethics Committee, and additionally,
for the gabapentin versus placebo trial, from the ethics
committees of the participating institutions, Princess
Alexandra Hospital, Brisbane and the Port Kembla
Hospital. Because of the increased risk of sudden death
from celecoxib, in late 2004 the Therapeutic Goods
Administration instructed all trials using celecoxib to
cease—including ours.
The economic evaluation of these trials is primarily
a cost-minimization analysis. This approach was
chosen because medication and resource use were rou-
tinely measured during follow-up, but health outcome
data were monitored during the trial period only; thus
a full economic evaluation was not possible. Neverthe-
less, we address this shortcoming by undertaking cost-
effectiveness and cost-utility analyses by extrapolating
the pain scores for responders and nonresponders from
the trial for the time horizon modeled. The pain index
was recorded on a visual analog 0–10 scale with 0 (no
pain) and 10 (extreme pain); scores were categorized
and converted to a utility weight to estimate quality-
adjusted life-years (QALYs). Although not ideal, this
approach does give some relativity to the cost minimi-
zation analysis by estimating the incremental cost per
point decrease on the pain scale and the incremental
cost per QALY gained.
Cost of N-of-1 Trials
We estimated the costs of setting up and running a fully
funded university-based N-of-1 trials service based on
our experience with the staff time and costs of running
the N-of-1 trials funded from research grants from
2003 to 2005. All costs are expressed in Australian
dollars. Costs included a ﬁxed component for trial
establishment that is independent of the number of
patients in a trial, and a variable component per
patient for each N-of-1 trial. The ﬁxed establishment
costs were estimated at $23,280 per trial. These com-
prised staff costs for protocol development ($8130),
funding applications ($4730), ethics applications and
business agreements ($3000), preparation of forms
and questionnaires ($4350), database development
($2200) and design/preparation of medication packs
($870). The costs of N-of-1 trials per patient included
the costs of recruitment, administration, data collec-
tion and analysis, generation and feedback of results
and 12 months follow-up of health and economic out-
comes. These totaled $610 for each patient for the
celecoxib/paracetamol trial and $577 for each patient
for the gabapentin/placebo trial.
Because the N-of-1 trials are an ongoing service,
only a proportion of the total ﬁxed costs can be
assigned to those who have participated so far. There-
fore, for the ﬁxed costs, we have assumed the protocol
will be valid for 200 participants in each trial, and
calculated a ﬁxed cost per patient of $116 based on
this number. The ﬁxed costs and patient trial costs
were subject sequentially to the university infrastruc-
ture charge of 50%, a surcharge of 20% for internal
infrastructure and then the statutory goods and ser-
vices tax of 10%. In this scenario, the total cost per
patient is set at $1373 for celecoxib/paracetamol trials
and $1438 for gabapentin/placebo trials. These costs,
and the number of participants, are later varied in a
sensitivity analysis.
Modeling
Structure of the model. A decision analysis model with
two arms: “N-of-1 trial” and “No trial” was con-
structed using TreeAge Pro Software [14]. Within the
N-of-1 arm, there is a chance (probability) that the
intervention medication (celecoxib and gabapentin) is
better than the alternative medication. The alternative
medication for each trial is the set of other medications
used by participants, for example, analgesics (includ-
ing paracetamol), opioids, and nonsteroidal anti-
inﬂammatory drugs. These alternatives are used for the
economic evaluation, rather than placebo in the gaba-
pentin trial and paracetamol in the celecoxib trial,
because participants used these medications for pain
rescue during the trial and used these before and/or after
the trial during follow-up. Within each arm of the
model, there are ﬁve “health states” based on the
observed pattern of medication use and the probability
of survival. The health states are: intervention medica-
tion only, intervention plus other medications, other
medications only, no medications, and dead. Using a
semi-Markov process with monthly cycles, patients
transition between medications or can die (at the Aus-
tralian age-speciﬁc all-cause mortality rate [15]. This
approach allows “leakage” of those shown to be non-
responsive to the intervention medication to use the
intervention medication, and vice versa. The “No trial”
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comparator follows the same pathway but without
testing of which medication is best. The model used for
the evaluation of both trials is summarized in Figure 1.
Assumptions used in the base-case model
1. Response status is deﬁned by an equal weighting
of the differential response ﬁve outcomes: pain,
functional limitation, adverse event frequency and
preferred medication for both trials as described
earlier in the methods. Responders are deﬁned as
those showing a superior response to celecoxib
compared with SR paracetamol or gabapentin
compared with placebo.
2. Those participants showing no difference between
medications or a superior response to SR parac-
etamol or placebo are deﬁned as nonresponders
and would continue on SR paracetamol or no
additional medication, respectively.
3. Response rates used in estimates are those from
the series of completed trials conducted for this
project (i.e., 17.1% for celecoxib and 24.0% for
gabapentin) [12,13].
4. The use of the intervention medication by
Responders is that observed in the 12 months of
follow-up from the trials; the rates of use of the
intervention medication only, intervention medi-
cation in combination with other medication, and
other medication are constant.
5. Nonresponders are allowed to continue use of
celecoxib or gabapentin in the N-of-1 arm but,
because participants are informed of their
response outcome, they discontinue use of the
intervention medication at a rate of 50%
annually.
6. Medication use in the no-trial arms is estimated
from the trial data. For the celecoxib/paracetamol
analysis, the pretrial data on medication use were
used; for the gabapentin analysis, we assumed the
use of gabapentin was double that observed for
nonresponders over the 12-months follow-up.
This assumption was made because pretrial data
indicated very low use of gabapentin. The
expected use of gabapentin in the absence of a trial
is much greater than reported for the pretrial
period because all patients are expected to use
gabapentin for an unknown period (NB: patients
were recruited into the N-of-1 trial when the cli-
nician considered a trial of gabapentin). In the
absence of a trial some would respond and others
Use intervention drug alone
Use intervention drug plus other
Use other
No drug
Dead
Intervention drug Better
Use intervention drug alone
Use intervention drug plus other
Use other
No drug
Dead
Intervention drug NOT better
N-of-1
Use intervention drug alone
Use intervention drug plus other
Use other
No drug
Dead
No trial
Trial vs. No trial
Figure 1 Illustration of the Decision Model with medication use/health states.
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would persist with using it even in the absence of
a true response.
7. An annual discontinuation rate of 25% of the
intervention medication is used in the no-trial
arm.
8. Compliance with medications is 100%.
9. The full dispensing price for all medications (as
per the PBS Schedule) is used.
10. The pain scores used for responders, and conse-
quently utility weights, are the mean scores
reported by responders when using the interven-
tion medication. For nonresponders, the mean
scores of intervention and comparator medica-
tion are used, and for the no-trial arm, the mean
of the all scores (intervention and comparator
medication for responders and nonresponders) is
used.
11. The pain scores were mapped to the EQ-5D by
categorizing scores as no pain or discomfort 1;
moderate pain or discomfort 6, and extreme
pain or discomfort >6. To approximate a utility
weight, the EQ-5D scoring algorithm for the UK
was used [16] with the assumption that there were
no problems with mobility, personal care, usual
activities or anxiety/depression.
12. The pain score and utility weight are constant for
the duration of the time horizon modeled.
Variables used in the models. The proportions using
each medication are calculated from the N-of-1 trials
using the means over 12 months’ follow-up. Upper
and lower values were calculated from the 95% con-
ﬁdence intervals. Similarly, costs for each medication
were calculated from observed medication usage over
12 months. This approach implicitly accounts for dif-
ferent daily doses. The mean costs, and 95% conﬁ-
dence intervals are used for the upper and lower
values. The time horizon used in the base-case model is
5 years and is varied in sensitivity analyses up to end of
life. All costs (and QALYs) are discounted at 5% [17].
Variables used in the models are presented in Tables 1
and 2.
Sensitivity and Scenario Analyses
One-way sensitivity analyses were performed on all
variables to identify the variables that have the greatest
impact on the incremental costs and the incremental
cost per QALY gained for both models, including
assessing the effects of scale on cost-effectiveness. A
scenario was developed to assess a policy where high
cost pharmaceuticals require that an individual’s
response must be proven through an N-of-1 trial
before the medication is approved for government
subsidy to that individual. In addition, an analysis of
responders compared with nonresponders is presented.
This analysis is equivalent to an evaluation of the
efﬁcacy and costs of an intervention medication com-
pared with the control. Incremental costs and QALYs
are estimated for the intervention medication.
Results
Within the range of parameters chosen for the base-
case models, the “N-of-1 trial” option costs signiﬁ-
cantly more per person than the alternative of “No
trial” for both trials conducted. Nevertheless, the cost
of the trial was partially offset by more efﬁcient use of
medications through nonresponders using less of the
high cost medication. These cost-offsets were greater
for the gabapentin/placebo trial ($569) than for the
celecoxib/paracetamol trial ($221), resulting in incre-
mental costs of $869 and $1152 for the two trials,
respectively (Table 3).
The pain scores, measured during the trials only,
show that the average level of pain for participants in
N-of-1 trials was reduced by 0.278 and 0.113 points
for the gabapentin/placebo and celecoxib/paracetamol
trials compared with the “No trial” alternative. Thus,
an N-of-1 trial can reduce pain through efﬁcient medi-
cation use. Although these reductions in pain score
may appear small, they contain the scores from
responders and nonresponders.
Converting the pain scores into utility weights, and
then to QALYs, the N-of-1 trials lead to an additional
0.126 QALYs for the gabapentin/placebo trial and
0.039 QALYs for the celecoxib/paracetamol trial over
5 years compared with no trial.
The incremental cost per one-point reduction on the
10-point pain scale is $3,125 and $10,199 for the
gabapentin/placebo and celecoxib/paracetamol trials,
respectively, and the incremental cost per QALY
gained is $6,896 and $29,550, respectively.
Sensitivity Analyses
Varying the time horizon modeled shows that greater
cost-offsets are achieved with longer horizons (i.e., the
incremental cost is smaller) for both trials; similarly,
the QALYs gained also increase with increased time
horizons. Using a horizon to the end of life, the ICERs
were $1,725 and $10,278 per QALY gained.
Tornado diagrams are used to depict the change in
expected costs from changing individual parameter
values within their expected range (Tables 1 and 2); the
factor that has the greatest effect is depicted at the top
of the diagram down to those with the smallest effect
on results. Tornado diagrams are presented for the
incremental costs for each trial (Figs. 2 and 3) and the
incremental cost per QALY gained (Figs. 4 and 5)
using the 5-year time horizon.
For both N-of-1 trials, the rates of use of the inter-
vention medication in the no-trial alternative and the
nonresponders were highly important factors affecting
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the incremental costs and ICERs. That is, the probabil-
ity of use of the intervention medication by nonre-
sponders and without a trial makes a substantial
difference to the costs.
The variable costs to conduct N-of-1 trials were a
key driver of the costs and ICERs in all four tornado
diagrams. Assumption of economies of scale were
obtained, the variable costs could be reduced by
approximately 50% for the celecoxib/paracetamol
trial and 40% for the gabapentin/placebo trial; this
would result in incremental costs and ICERs that are
47% and 44% lower compared with the base case.
The costs of the intervention medications had rela-
tively little effect on the incremental costs or ICERs;
more important was the cost of the alternative medi-
cations used—both in combinations with the inter-
vention medication and without the intervention
medication. When lower “other” medication costs
were used, the incremental costs and the ICERs
increased as the difference in costs between running an
N-of-1 trial and the alternative were greater. As such,
the beneﬁts of N-of-1 trials were reduced.
Changes in the probabilities of responding to cele-
coxib in the celecoxib/paracetamol trial had little effect
on the incremental cost but a large effect on the ICER;
this large effect on the ICER occurred when the addi-
tional beneﬁt of celecoxib compared with other medi-
cations approached zero, resulting in a very large
ICER. In contrast, the probability of responding to
gabapentin was a key factor affecting the incremental
costs with a relatively smaller effect on the ICER.
Because gabapentin is required to be prescribed by
specialists, lower response rates tend to reﬂect
decreased usage by nonresponders and hence, lower
incremental costs. Variation in the utility weights used
and the pain scores had substantial effects on ICERs.
Changes to other factors, such as the initial age and
discount rates, had relatively little effect on results.
Overall, from examining both tornado diagrams,
the important features of N-of-1 trials affecting the
Table 1 Variables used in the celecoxib/paracetamol model
Variable
Base-case
value
Lower
value
Upper
value Notes
Cost of trial
Total ﬁxed costs ($) 23,200 11,800 39,600 Based on actual staff inputs and
infrastructure costsVariable cost per patient ($) 1,257 628 1,500
N participants 200 50 2,000
Celecoxib responders
Proportion celecoxib better 0.171 0.085 0.320 Celecoxib/paracetamol N-of-1 trial; lower
and upper 95% CI; mean at 12 months
f/u
Use celecoxib only 0.194 0.158 0.231
Use celecoxib and other meds 0.278 0.167 0.388
Use other meds only 0.333 0.278 0.389
No meds 0.194 0.146 0.243
Celecoxib nonresponders
Use celecoxib only 0.083 0.000 0.093 Celecoxib/paracetamol N-of-1 trial; lower
and upper 95% CI; mean at 12 months
f/u
Use celecoxib and other meds 0.185 0.000 0.206
Use other meds only 0.667 0.533 0.800
No meds 0.065 0.064 0.067
Celecoxib discontinuation rate (annual) 0.500 0.000 1.000
No trial
Use celecoxib only 0.089 0.000 0.691 Celecoxib/paracetamol N-of-1 trial; lower
and upper 95% CI; pretrial usageUse celecoxib and other meds 0.375 0.309 0.691
Use other meds only 0.500 0.000 0.750
No meds 0.036 0.000 0.072
Celecoxib discontinuation rate (annual) 0.250 0.000 0.500
Other factors
Cost of celecoxib ($) 34.74 9.89 59.59 Calculated from observed daily doses over
12 months f/u, using PBS costs; lower
and upper 95% CI
Cost of other meds ($) 17.90 8.32 44.12
Cost of celecoxib plus other meds ($) 39.86 20.90 58.82
Pain score celecoxib responder 3.89 3.19 4.59 Mean score of responders for periods of
gabapentin use during trial; lower and
upper 95% CI
Pain score celecoxib nonresponder 4.55 4.20 4.89 Mean score of nonresponders during trial;
lower and upper 95% CI
Pain score no trial 4.55 4.25 4.85 Mean from all in trial; lower and upper
95% CI
Utility—celecoxib responder 0.78 0.47 1.00 Calculated from proportion with no,
moderate, and extreme pain mapped to
the EQ-5D
Utility—celecoxib nonresponder 0.67 0.64 0.71
Utility—no trial 0.68 0.65 0.71
Probability of death Age-speciﬁc mortality rates [15]
Start age (years) 64.2 54.2 74.2 Observed in trial; lower and upper 95% CI
Duration (months) 60 12 End of life
Discount rate (annual) 5.00% 0.00% 10.00% [17]
CI, conﬁdence interval; meds, medications.
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ICER were the assumptions around the no-trial alter-
native (including the use of the intervention drug and
other drugs, and the discontinuation rate). Changes in
health outcomes, including the utility weights, were
key factors, as was the probability the intervention
drug was better than the comparator. Features of
N-of-1 trials that were less important were the ﬁxed
costs, discount rates and the mix of drugs used by
responders and nonresponders.
A scenario where prescribing of the high cost inter-
vention medication is restricted to those who have
shown a positive response in an N-of-1 trial would
reduce the costs of the N-of-1 trial only; that is, the
pain scores and QALYs would remain unchanged
because the use of the medication in a nonresponder
has no effect on these outcomes (Table 4). Thus, this
restriction has some beneﬁt to controlling pharmaceu-
tical budgets and better use of medications.
The analysis of responders compared with nonre-
sponders within the N-of-1 trial is used to identify
the incremental cost and cost-effectiveness of the
intervention medication compared with the alterna-
tive medication (opposed to whether an N-of-1 trial
provides value for money compared with no trial).
The difference in medication costs for responders
versus nonresponders in the celecoxib versus SR
paracetamol trial were relatively small, whereas the
difference in costs between responders and nonre-
sponders in the gabapentin versus placebo trial were
substantially greater (Table 5). In contrast, respond-
ers in the celecoxib trial had a slightly greater reduc-
tion in pain score compared with responders in the
gabapentin trial. This difference in pain reduction
translated into greater difference in QALYs between
responders and nonresponders in the two trials. From
this responder analysis for gabapentin, an ICER of
$8764 per point reduced on the pain scale and
$28,439 per QALY gained were obtained. For the
celecoxib trial, ICERs were $389 and $522 per point
of pain reduced and QALY gained, respectively.
Table 2 Variables used in the gabapentin/placebo model
Variable
Base-case
value
Lower
value
Upper
value Notes
Cost of trial
Total ﬁxed costs ($) 23,200 11,800 39,600 Based on actual staff inputs and infrastructure
costsVariable cost per patient ($) 1,322 802 1,600
N participants 200 50 2,000
Gabapentin responders (proportions)
Gabapentin responders 0.244 0.083 0.392 Gabapentin/placebo N-of-1 trial; lower and
upper 95% CIUse gabapentin only 0.227 0.154 0.300
Use gabapentin and other meds 0.603 0.406 0.799
Use other meds only 0.170 0.161 0.180
No meds 0.000 0.000 0.000
Gabapentin nonresponders (proportions)
Use gabapentin only 0.071 0.068 0.075 Gabapentin/placebo
N-of-1 trial; lower and upper 95% CIUse gabapentin and other meds 0.146 0.132 0.159
Use other meds only 0.614 0.550 0.679
No meds 0.169 0.161 0.176
Gabapentin discontinuation rate (annual) 0.500 0.000 1.000 Assumed
No trial (proportions)
Use gabapentin only 0.143 0.136 0.149 Assumed 100% greater than nonresponder
Use gabapentin and other meds 0.291 0.263 0.319 Assumed 100% greater than nonresponder
Use other meds only 0.566 0.601 0.435 Residual
No meds 0.000 0.000 0.097 Min from responders; high value = observed
pretrial
Gabapentin discontinuation rate (annual) 0.250 0.000 0.500
Other factors
Cost of gabapentin ($) 113.78 51.80 155.41 Calculated from observed daily doses over
12 months f/u, using PBS costs; lower and
upper 95% CI
Cost of other meds ($) 83.56 53.08 112.55
Cost of gabapentin plus other meds ($) 197.34 104.88 267.96
Pain score gabapentin responder 3.64 3.03 4.24 Mean score of responders for periods of
gabapentin use during trial; lower and upper
95% CI
Pain score gabapentin nonresponder 4.13 3.83 4.43 Mean score of nonresponders during trial;
lower and upper 95% CI
Pain score no trial 4.29 4.03 4.54 Mean from all in trial; lower and upper 95%
CI
Utility—gabapentin responder 0.74 0.53 0.96 Calculated from proportion with no,
moderate, and extreme pain mapped to the
EQ-5D
Utility—gabapentin nonresponder 0.71 0.68 0.75
Utility—no trial 0.69 0.66 0.72
Probability of death Age-speciﬁc mortality rates [15]
Start age (years) 57.6 41.8 73.4 Observed in trial; lower and upper 95% CI
Duration (months) 60 12 End of life
Discount rate, % (annual) 5.00 0.00 10.00 [17]
CI, conﬁdence interval.
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Discussion
This study provides important evidence that within the
Australian context N-of-1 trials offer a realistic option
for increasing patients’ access to high-cost medica-
tions, under speciﬁc circumstances. In particular, the
characteristics of the gabapentin trial appeared more
economically viable than the celecoxib trial. Gabapen-
tin is relatively more expensive than celecoxib, and
reducing its use in nonresponders results in greater
cost-offsets compared with the cost-offsets obtained
from reducing use of celecoxib in nonresponders. In
addition, the proportion of responders in the gabap-
entin trial were greater than those in the celecoxib
trial, and the reduction in pain score by gabapentin
responders was greater than the pain reduction by
celecoxib responders. Therefore, the gabapentin trial
resulted in substantially greater QALYs than those
obtained from the celecoxib trial.
Our analysis of the costs of developing, setting up
and running N-of-1 trials showed a relatively high cost
per individual trial. Nevertheless, the modeling sug-
gests that these costs may partially recouped if the cost
differential between the two therapies is sufﬁciently
high, as illustrated by the gabapentin/placebo trials. In
contrast, when the cost-differential is smaller, as in the
celecoxib/SR-paracetamol trials, it was cheaper to
allow every patient to use celecoxib. This concurs with
Table 3 Results for the N-of-1 trial prescribing strategies:costs,
outcomes and cost-effectiveness of the N-of-1 trials vs. no trial
Gabapentin vs.
placebo
Celecoxib vs.
paracetamol
5 years (base case)
Cost: no trial ($) 5,654 1,193
Cost: N-of-1 ($) 6,523 2,346
Incremental cost ($) 869 1,152
Pain score: no trial 4.290 4.550
Pain score: N-of-1 4.012 4.437
Reduction in pain (points) 0.278 0.113
QALYs: no trial 3.141 3.045
QALYs: N-of-1 3.267 3.084
Incremental QALYs 0.126 0.039
Incremental cost per point
reduction in pain ($)
3,125 10,199
Incremental cost per QALY
gained ($)
6,896 29,550
12 months
Cost: no trial ($) 1,539 326
Cost: N-of-1 ($) 2,722 1,592
Incremental Cost ($) 1,183 1,267
QALYs: no trial 0.821 0.801
QALYs: N-of-1 0.853 0.811
Incremental QALYs 0.032 0.010
Incremental cost per point
reduction in pain ($)*
4,254 11,209
Incremental cost per QALY
gained ($)
36,958 126,661
End of life
Cost: no trial ($) 15,279 2,791
Cost: N-of-1 ($) 15,893 3,809
Incremental Cost ($) 614 1,018
QALYs: no trial 9.040 7.604
QALYs: N-of-1 9.396 7.703
Incremental QALYs 0.356 0.099
Incremental cost per point
reduction in pain ($)*
2,209 9,004
Incremental cost per QALY
gained ($)
1,725 10,278
*The pain score, obtained from the trials, is constant for all time horizons modeled.
QALY, quality-adjusted life-year.
Table 4 Scenario where high-cost medication is available to
N-of-1 responders only. Costs and cost per QALY gained com-
pared with no trial over 5-years
Gabapentin Celecoxib
No trial N-of-1 No trial N-of-1
Cost ($) 5,654 6,251 1,193 2,255
Incremental cost ($) 597 1,062
QALYs 3.141 3.267 3.045 3.084
QALYs gained 0.126 0.039
ICER ($) 4761 26,934
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years.
Table 5 Results for the N-of-1 trial prescribing strategies:
costs, outcomes and cost-effectiveness of gabapentin vs. placebo
and celecoxib vs. paracetamol
Gabapentin vs.
placebo
Celecoxib vs.
paracetamol
5 years (base case)
Cost: nonresponder ($) 5,512 2,301
Cost: responder ($) 9,806 2,558
Incremental cost per
responder ($)
4,294 257
Pain score: nonresponder 4.130 4.550
Pain score: responder 3.640 3.890
Reduction in pain (points) 0.490 0.660
QALYs: nonresponder 3.230 3.000
QALYs: responder 3.381 3.492
Incremental QALYs 0.151 0.492
Incremental cost per point
reduction in pain ($)
8,764 389
Incremental cost per QALY
gained ($)
28,439 522
12 months
Cost: nonresponder ($) 2,515 1586
Cost: responder ($) 3,391 1624
Incremental cost per
responder ($)
876 39
QALYs: nonresponder 0.841 0.789
QALYs: responder 0.891 0.918
Incremental QALYs 0.050 0.129
Incremental cost per point
reduction in pain ($)*
1,788 58
Incremental cost per QALY
gained ($)
17,525 298
End of life
Cost: nonresponder ($) 12,761 3,676
Cost: responder ($) 26,067 4,454
Incremental cost per
responder ($)
13,306 778
QALYs: nonresponder 9.302 7.493
QALYs: responder 9.695 8.723
Incremental QALYs 0.393 1.230
Incremental cost per point
reduction in pain ($)*
27,156 1179
Incremental cost per QALY
gained ($)
33,859 633
*The pain score, obtained from the trials, is constant for all time horizons modeled.
QALY, quality-adjusted life-years.
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the ﬁndings of Pope et al. [8]. The additional costs of
the N-of-1 trials reported here were $869 and $1152
for the gabapentin/placebo and celecoxib/paracetamol
trials. Moreover, N-of-1 trials improve clinical and
health outcomes. We estimated modest QALY gains of
3.8% and 1.3% for two trials, which when combined
with costs, produced ICERs of $6,896 and $29,550
per QALY gained for the two trials. Nevertheless, over
and above any costs or cost-offsets, there is value to
both clinicians and patients in having knowledge that
they are being prescribed medications to which they
will respond positively, and thus, these analyses may
understate the full economic beneﬁt of N-of-1 trials.
Some of the assumptions chosen for the base-case
models were simpliﬁcations and may be unlikely to be
observed in the real world. For example, persistence
with long-term therapy is generally poor (approxi-
mately 50%), particularly after the ﬁrst 6 months [18].
Nevertheless, persistence is expected to be greater
when the patient is given the knowledge that the medi-
cation is effective for them, and is expected to be much
lower when the patients are told the medication does
not work for them. A reduction in the number of
responders persisting with the more expensive medica-
tion (or the duration of use by responders) would have
the effect of reducing the ICERs (assuming quality of
life was maintained). Conversely, a “leakage” effect of
nonresponders resuming the more expensive medica-
tion will reduce cost-effectiveness. The long-term rates
of the opposing effects of persistence and leakage are
unknown; however, we have attempted to capture
these effects in our model using data reported from
12 months of follow-up.
Additional cost-offsets not included in our analysis
may come from a reduction in physician time for medi-
cation review and treatment of adverse reactions for
those in the N-of-1 trial; however, the size of this effect
is unknown. Another limitation of the analysis is the
need to extrapolate health outcomes from the 12-week
trial for the modeled time horizon. In future, we rec-
ommend that follow-up data collection should include
the clinical measures used to identify responders and
the use of a utility instrument such as the EQ-5D.
Similarly, the “No trial” group modeled in the analysis
was, effectively, a hypothetical cohort. Ideally, testing
the effectiveness and cost-effectiveness of N-of-1 trials
requires participants to be randomized to standard
care or an N-of-1 trial.
The method of patient selection for these trials may
have affected response rates and therefore estimates
of cost-effectiveness. Requests for the celecoxib/
paracetamol trials were mostly patient-generated and
therefore attracted people who were uncertain about
the effectiveness of their medication. The gabapentin/
Prob no meds—Nonresponder
Age
Prob use celecoxib only—Responder
Prob no meds—Responder
Cost celecoxib
Prob use celecoxib only—Nonresponder
Discount rate—Costs
Prob use celecoxib plus other meds—Responder
Prob celecoxib better
Prob no meds—No Trial
Prob use celecoxib plus other meds—Non-responder
Fixed cost of N-of-1 trial
Cost other meds
Celecoxib discontinuation rate—Nonresponder
Cost celecoxib plus other meds
Time horizon
Prob use celecoxib plus other meds—No trial
Celecoxib discontinuation rate—No trial
Prob use celecoxib only—No trial
Total patients in trial
Variable cost of N-of-1 trial
Change in incremental cost from baseline ($1152)
Expected cost using the high parameter value
Expected cost using the low parameter value
–600               –400                –200 0                   200                 400                  600
Figure 2 Sensitivity analysis around incremental costs for the celecoxib/paracetamol model.The baseline incremental cost of the “N-of-1 trial” compared
with “No trial” was $1152.
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placebo trials were initiated by doctors who were
uncertain of gabapentin’s effectiveness in patients on
long-term gabapentin, who had shown some response
to a 2- to 3-week trial of gabapentin.
The minimum and maximum doses used in the
gabapentin trial were below those recommended for
the treatment of neuropathic pain (900–3000 mg/day)
[19]. Both of these factors could have reduced the
number of responders. A lower number of responders
results in lower total costs in the N-of-1 trial option. In
turn, this requires a shorter duration of continuous
treatment for the trial arm to become more cost-
effective than the usual care arm.
The responder analysis, comparing the intervention
medication with the set of “other medications,” is a
spin-off beneﬁt of N-of-1 trials. The responder analysis
can allow efﬁcacy, costs and cost-effectiveness of an
intervention medication to be established and/or con-
ﬁrmed in addition to identifying the suitability of a
medication for an individual. It is possible that non-
random biases may occur in the N-of-1 trial process,
despite double blinding, if patients know that the
results will inﬂuence their treatment decisions. For
example, patients may exaggerate beneﬁts in the
periods when they believe they are taking the more
expensive medication [6].
Many of the practical issues of conducting post and
telephone N-of-1 trials throughout Australia with
minimal demands on prescribing doctors have been
addressed by the N-of-1 trial service. Nevertheless, the
trials were performed in relatively small numbers of
consenting, motivated patients. The provision of trials
in a timely fashion to large numbers of community or
hospital patients would present considerable logistical
challenges, but would not be impossible. One option
would be an extension of the current authority-
prescribing system, where doctors request approval for
speciﬁc subsidized medications under a special author-
ity. Funding of the extension of such a service could
come from those who would beneﬁt namely govern-
ment, pharmaceutical companies and patients. Gov-
ernment stands to gain by making savings to the PBS
budget. Pharmaceutical companies could beneﬁt if the
N-of-1 trials are a condition of listing for previously
unlisted medications or if they are offered a premium
price for medications in responders. That is, pharma-
ceutical companies could show a greater beneﬁt by
reporting the effect in responders compared with an
alternative treatment. The price of the pharmaceutical
could be increased to the point where the ICER was
bordering on the acceptable threshold for government
subsidy/funding, and thus, a higher price could be
Prob use gabapentin only—Nonresponder
Prob use gabapentin only—No trial
Cost gabapentin
Prob use gabapentin plus other meds—Nonresponder
Prob no meds—Nonresponder
Prob use gabapentin only—Responder
Discount rate—Costs
Fixed cost of N-of-1 trial
Prob use gabapentin plus other meds—No trial
Age
Cost other meds
Cost gabapentin plus other meds
Prob no meds—No Trial
Prob use gabapentin plus other meds—Responder
Time horizon
Gabapentin discontinuation rate—Nonresponder
Total patients in trial
Variable cost of N-of-1 trial
Gabapentin discontinuation rate—No Trial
Prob gabapentin better
Change in incremental cost from baseline ($869)
Expected cost using the high parameter value
Expected cost using the low parameter value
–1000         –800         –600         –400         –200 0             200           400           600            800
Figure 3 Sensitivity analysis around incremental costs for the gabapentin/placebo model.The baseline incremental cost of the “N-of-1 trial” compared
with the “No trial” was $869.
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obtained with the restriction that the medication is
prescribed for responders only. Patients may beneﬁt
from clinical decisions based on individualized evi-
dence; however, there may be strong resistance to pay
for a test that may exclude them from taking a medi-
cation they think they need.
We analyzed a scenario where mandatory partici-
pation in an N-of-1 trial is a condition for getting
affordable access to a desired medication and showed
greater cost-offsets could be achieved; however, man-
datory participation in an N-of-1 trial might also be
considered a signiﬁcant ethical or moral issue. An
appeals mechanism might be necessary for those who
refuse to consent to an N-of-1 trial, and for nonre-
sponders disaffected by the denial of affordable
access to medication. Furthermore, N-of-1 trials are
double-blind studies for which informed consent is a
standard requirement. Ethics guidelines state that
refusal to consent to entry in a trial should never
compromise the doctor–patient relationship [20].
Nevertheless, clinicians commonly conduct informal
(and methodologically inadequate) N-of-1 trials when
they try a medication in a patient and judge a clinical
response; and this occurs in the face of the issues
outlined above.
Several questions remain unanswered about the
broader application of N-of-1 trials. How can they be
administered successfully in patients with cognitive
impairment or for whom English is a second language?
Should there be an item number or a Practice Incentive
Payment for the effort required by doctors requesting
them? Will they be accepted by doctors as a tool for
rational prescribing or just perceived as another
barrier to prescribing? Will they be accepted by
patients who stand to lose affordable access to a medi-
cation that they may believe is helping them? A mar-
keting campaign would be required to explain the
beneﬁts of N-of-1 trials as a tool for tailoring treat-
–50,000 –25,000 0 25,000 50,000 75,000 100,000 125,000 150,000
Prob no meds—Nonresponder
Prob use celecoxib only—Responder
Prob no meds—Responder
Cost celecoxib
Prob use celecoxib only—Nonresponder
Discount rate—Costs
Prob use celecoxib plus other meds—Responder
Prob no meds—No trial
Prob use celecoxib plus other meds—Nonresponder
Fixed cost of N-of-1 trial
Cost other meds
Age
Celecoxib discontinuation rate—Nonresponder
Cost celecoxib plus other meds
Discount rate—Health outcomes
Prob use celecoxib plus other meds—No trial
Celecoxib discontinuation rate—No trial
Prob use celecoxib only—No trial
Pain score—No trial
Pain score—Nonresponder
Utility—Responder
Total patients in trial
Utility—No trial
Utility—Nonresponder
Variable cost of N-of-1 trial
Time horizon
Pain score—Responder
Prob celecoxib better
Change in ICER from baseline 
(Incremental cost/QALY = $29,216; incremental cost/pain point = $10,199)
ICER using the high parameter value
ICER using the low parameter value
x10
Figure 4 Sensitivity analysis around incremental cost per quality-adjusted life-year (QALY) gained for the celecoxib/paracetamol model. The baseline
incremental cost-effectiveness ratio (ICER) of the “N-of-1 trial” compared with “No trial” was $29,216.
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ment to individual patients so these trials are not just
seen as a method of cutting costs for the PBS.
Collectively, these issues restrict the range of medi-
cations suitable for an N-of-1 trial prescribing strategy
(Table 6). Nevertheless, suitable medications would
include expensive medications for the symptomatic
treatment of chronic conditions where there is a low
overall response rate but a high and unpredictable
variability in individual response. The difference in
costs for responders and nonresponders is a key factor
in being able to make cost-savings from conducting
N-of-1 trials. If there is an alternative medication for
nonresponders, it needs to be relatively cheap. N-of-1
trials may also have a role in targeting the use of
medications that have a predictably superior clinical
response to alternatives but with an unpredictably
worse adverse event proﬁle.
Thanks to the General Practice Evaluation Program and the
Department of Health and Aged Care for funding; Glaxo-
SmithKline Consumer Healthcare for supply of medication,
placebos, and funding and for their invaluable support; Pro-
fessor Paul Glasziou, Professor Christopher Del Mar, Asso-
ciate Professor Geoffrey Mitchell for advice on design and
conduct of the trials the N-of-1 trial service staff Norma
McNairn, Grace McBride, Robyn Brown and, Donna-Marie
–15,000 0 15,000 30,000 45,000 60,000 75,000
prob use gabapentin only—Nonresponder
prob use gabapentin only—No trial
Cost gabapentin
prob use gabapentin plus other meds—Nonresponder
prob no meds—Nonresponder
prob use gabapentin only—Responder
Discount rate—Costs
Fixed cost of N-of-1 trial
Age
prob use gabapentin plus other medsv—No trial
Discount rate—Health outcomes
Cost other meds
Cost gabapentin plus other meds
prob no meds—No trial
prob use gabapentin plus other meds—Responder
Pain score—Responder
gabapentin discontinuation rate—Nonresponder
Total patients in trial
Variable cost of N-of-1 trial
Prob gabapentin better
Gabapentin discontinuati on rate—No trial
Utility—Responder
Pain score—Nonresponder
Time horizon
Utility—Nonresponder
Pain score—No trial
Utility—No trial
Change in ICER from baseline 
(Incremental cost/QALY = $6896; incremental cost/pain point = $3125)
ICER using the high parameter value
ICER using the low parameter value
Figure 5 Sensitivity analysis around incremental cost per quality-adjusted life-year (QALY) gained for the gabapentin/placebo model. The baseline
incremental cost-effectiveness ratio (ICER) of the “N-of-1 trial” compared with the “No trial” was $6896.
Table 6 Features of medications suited to an N-of-1 trial pre-
scribing strategy
Pharmacological features
Indicated for symptomatic treatment of chronic conditions
Rapid onset of action
Short washout period
Clinical features
Variable clinical response that cannot be predicted without a trial
Superior clinical response to alternative but with a more serious
adverse event proﬁle
Low overall response rate
Other features
High differential in price compared with alternatives
Limited demand at a national level
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